ACADIA to Host Conference Call and Webcast on Tuesday, March 6, 2012,
at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Feb. 28, 2012—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
utilizing innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system disorders,
today announced that it will report its financial results for the fourth
quarter and year ended December 31, 2011 on Tuesday, March 6, 2012,
after the U.S. financial markets close. ACADIA's management will host a
conference call and webcast on Tuesday, March 6, 2012, at 5:00 p.m.
Eastern Time to discuss ACADIA’s financial results and development
programs.
The conference call may be accessed by dialing 866-510-0711 for
participants in the U.S. or Canada and 617-597-5379 for international
callers (reference passcode 14152077). A telephone replay of the
conference call may be accessed through March 20, 2012 by dialing
888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for
international callers (reference passcode 69685455). The conference call
also will be webcast live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until March 20,
2012.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to
fuel drug discovery and clinical development of novel treatments for
central nervous system disorders. ACADIA has four product candidates in
clinical development including pimavanserin, which is in Phase III
development as a potential first-in-class treatment for Parkinson’s
disease psychosis. ACADIA also has a product candidate in Phase II
development for chronic pain and a product candidate in Phase I
development for glaucoma, both in collaboration with Allergan, Inc., and
AM-831 in Phase I development for schizophrenia in collaboration with
Meiji Seika Pharma Co., Ltd. All of the product candidates in ACADIA’s
pipeline emanate from discoveries made using its proprietary drug
discovery platform. ACADIA maintains a website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs either alone or with a partner,
including clinical trials, and the benefits to be derived from ACADIA’s
product candidates, in each case including pimavanserin. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that
past results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2010
as well as other subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements
are qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive
Vice President,
Chief Financial Officer and Chief Business
Officer
(858) 558-2871